Tango Therapeutics TNGX Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's cash provided by (used in) financing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's cash provided by (used in) financing activity, including discontinued operation?
- Tango Therapeutics (TNGX) reported cash provided by (used in) financing activity, including discontinued operation of $79.85M in Q1 2026.
- How has Tango Therapeutics's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
- Tango Therapeutics's cash provided by (used in) financing activity, including discontinued operation increased by 3992200.0% year-over-year, from $2K to $79.85M.
- What is the long-term trend for Tango Therapeutics's cash provided by (used in) financing activity, including discontinued operation?
- Over 3 years (2022 to 2025), Tango Therapeutics's cash provided by (used in) financing activity, including discontinued operation has grown at a 416.5% compound annual growth rate (CAGR), from $1.62M to $222.5M.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.